美国食品和药物管理局批准CERO Therapeutics首次对人类进行CER-1236新型AML治疗试验. CERo Therapeutics gains FDA approval for first-in-human trials of new AML treatment, CER-1236.

CERo治疗药物已经获得林业发展局批准,开始对其新的化合物CER-1236进行第一阶段临床试验,该化合物旨在治疗急性心髓白血病(AML)。 CERo Therapeutics has received FDA approval to start Phase 1 clinical trials for its new compound, CER-1236, aimed at treating acute myelogenous leukemia (AML). 该公司的铅化合物是一个叫CER-T的新型细胞免疫疗法平台的一部分,它可能同时治疗血细胞恶性肿瘤和固态肿瘤。 The company's lead compound is part of a novel cellular immunotherapy platform called CER-T, which could potentially treat both hematological malignancies and solid tumors. 第一次人间审判定于2025年初开始。 The first-in-human trial is set to begin in early 2025.